Management team

Dag Aarsland

Professor Dag Aarsland joined the Institute of Psychiatry, Psychology and Neuroscience, King’s College London, in January 2016, after having served as Professor of Clinical dementia research at the Alzheimer’s Research Centre at Karolinska Institute in Stockholm, Sweden for five years. He also is the Research Director of the Centre for Age-Related Disease at Stavanger University Hospital. His dementia research career spans 25 years and includes a variety of translational clinical research, including leading several large multicentre biomarker and clinical trials. Improving clinical measurement and implementing novel digital devices has been an emerging interest during the last five years.

He has 400 PubMed listed papers, with a current H-factor of 105 and 47000 citations (Google scholar).

Vaibhav Narayan

Vaibhav is currently Vice President, Research Technology at Janssen R&D, and RADAR-CNS project co-lead.  The Neuroscience Therapeutic Area at Janssen is pioneering a more personalized and holistic approach to therapeutic intervention that goes ‘beyond the pill’, to offer data-driven and science-based ‘integrated solutions’ for preventing, diagnosing, treating, and monitoring CNS diseases. Vaibhav’s work is currently focused on utilizing state-of-the-art informatics methods and digital technologies for developing markers for early diagnosis, disease progression, drug response and treatment monitoring in Alzheimer’s and Mood; and to develop novel ‘point-of-need’ tools and technologies for management of adherence and prediction of relapse in patients with Schizophrenia. 

Vaibhav joined Johnson and Johnson from Eli Lilly and Co., where he headed the Discovery and Biomedical Informatics group to enable Lilly’s translational, biomarker, and tailored therapeutics strategies.  Prior to Lilly, Vaibhav held multiple leadership roles in various small to mid-size biotech companies such as Celera Genomics, CuraGen Corporation and Vertex Pharmaceuticals during which time he participated in multiple landmark ‘Big Biology’ projects, including sequencing, assembly and analysis of the human genome (Human Genome Project) and elucidation of the first complete protein-protein interaction map of a whole organism. 

Vaibhav obtained his PhD from Yale University jointly from the Departments of Chemistry, and Molecular Biophysics & Biochemistry in 1998, and an Executive MBA from Kellogg School of Management, Northwestern University in 2009. 

Rouba Kozak

Rouba obtained her Ph.D. in neuroscience and eating behaviour from Henri Poincare University in France, and has an extensive background in cognitive neuroscience with focus on translational research. Specifically, she has focused on bridging the gap between mechanistic studies in preclinical animal models, which provide exquisite detail on how brain circuits control discrete behaviours, and the measurement of functional impact of new therapies in clinical settings (e.g. neuro-degenerative and neuro-psychiatric patient populations).

Rouba’s scientific training ranged from studies on the mechanisms of obesity to cognition, employing state-of-the- art behavioral and neurochemical sampling techniques; providing her with a unique ability to conceptualize and design experiments in support of programs spanning the wide-ranging disease domains covered in the Takeda portfolio. She has utilized complex behavioural and neurochemical methods to test hypotheses regarding etiologies of neuropsychiatric disorders, as well as to develop translational models to test the efficacy of novel pharmacotherapeutics for the enhancement of cognitive function.

Pieter Jelle Visser

Dr. Visser is a clinical epidemiologist working on the early diagnosis and treatment of AD. He will co-lead WP5. He has ample experience in leading European prospective multicentre data collection studies in AD (Descripa, EDAR, EMIF) and in reusing existing data (EMIF-AD). He is academic co-PI of EMIF-AD and WP co-lead in EPAD and in ROADMAP (via Maastricht University affiliation).

Yuhao Wu

Yuhao Wu is a senior software engineer in the Digital Phenotyping & Brain Health research group at the Big Data Institute, Nuffield Department of Population Health, at University of Oxford. Yuhao had delivered excellence in team and project management, and is dedicated to perform in multi-functional team collaborations. His interests focus on health informatics, machine learning and edge computing. Yuhao holds a bachelor and master's degree in computer science. Within RADAR-AD Yuhao leads WP4.

Herman Verheij

Herman Verheij studied organic chemistry at the University of Amsterdam, The Netherlands, where he also obtained a PhD in physical-organic chemistry. After a short stint as a post-doc researcher at the Wageningen University, where he developed organic solar cells, he joined the biggest worldwide supplier of screening chemistry, Specs, in 1998, as head of the department of Cheminformatics and Screening collaborations.

Together with a few colleagues he started Pyxis Discovery, where he also headed the Chemistry and Cheminformatics department. In 2010 he joined Top Institute Pharma as Senior Program Manager, where he managed the technological and financial execution of over 25 projects. Since 2016 he is one of the Senior Program Managers at Lygature, a Dutch not-for-profit foundation that acts as a catalyst for the development of new medical solutions for patients by driving public-private collaborations between academia, industry and society. Here he manages a.o. the worldwide RADAR-CNS and RADAR-AD projects, as well as the ReSToRe and PD-MIND consortia.

Vera Nies

Vera studied Medical Biology at the Radboud University Nijmegen, The Netherlands. During her studies she developed a keen interest for neuro-endocrinology and metabolism. She performed her final internship at the Salk Institute, La Jolla, USA, where she studied the urocortin system in relation to diabetes. After that she pursued a PhD in Molecular Metabolism, which she obtained from the State University Groningen (RUG) in May 2017. During her PhD she performed basic research with a clear translational signature, as she investigated the blood-glucose lowering effects of FGF1, a protein that is currently investigated for it potential to treat type 2 diabetes. After her PhD she gained experience in the pharmaceutical industry as a Regulatory Affairs Manager at Novartis, where she managed the portfolios of several oncology products.

She joined Lygature as a Program Manager in June 2018, where she is now involved with the day-to-day management of the IMI-funded projects RADAR-AD, RADAR-CNS, and ELF2. It is her ambition to stimulate innovation through collaboration, and to put science to practice so that it brings benefit to us all.

Andre Durudas

After receiving a business degree in insurance administration, Andre went on to study Chemical Engineering at the University of Applied Science in Münster, Germany. He then continued with his studies in the US and received his PhD in Immunology from the University of Texas Southwestern Medical Center in Dallas. Since 2010, Andre has been working in science project management, including collaboration projects funded by the US government (NIH, BARDA) as well as large-scale European-funded research projects in the FP7, Horizon2020 and IMI2 programs. In July 2016, he joined CMAST, a Belgian SME focusing on delivering Project Management, Consulting and Business Solutions to life science clients. In this role, Andre is subcontracted to Janssen Pharmaceutica to support the Project Leader in the two related IMI2 projects RADAR-CNS and RADAR-AD in all issues related to project management and contract compliance.